Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Walking and Thinking - Brain Activity During Complex Walking in Stroke

maanantai 1. kesäkuuta 2026 päivittänyt: Erika Franzén, Karolinska Institutet

Everyday life requires individuals to function in complex environments and perform tasks that involve the integration of motor and cognitive abilities. However, stroke often leads to impairments in motor-cognitive interaction, which can negatively affect mobility, balance, attention, and the ability to live independently. Although motor-cognitive performance has been identified as an important rehabilitation target after stroke, limited knowledge exists regarding the underlying brain function associated with these difficulties and how rehabilitation and exercise interventions can best address them.

Improving treatment for motor-cognitive difficulties after stroke, such as dual-task walking and navigation, remains a major challenge. An important step is developing assessment methods that accurately capture these impairments in ecologically valid settings that reflect real-world mobility demands. The investigators therefore aim to explore brain function during complex walking after stroke by investigating motor-cognitive performance and its neural correlates during three walking conditions: dual-task walking, navigation, and a combination of both. Non-invasive measures of brain activity using functional near-infrared spectroscopy (fNIRS) together with advanced real-time gait analysis will be used to better understand how stroke affects motor-cognitive functioning during complex walking tasks.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

BACKGROUND Stroke is one of the leading causes of mortality and disability in the world and the prevalence of stroke-related disability is expected to increase globally. In Sweden, about 29,000 individuals are affected by stroke every year. Individuals who have suffered a stroke often experience a high incidence of motor and cognitive impairment which are associated with insufficient blood supply and brain oxygenation. One main objective in post-stroke rehabilitation is fostering the capability to walk and navigate the community safely, aiming to uphold independence, facilitate social integration, and encourage active participation in society. Challenges such as impaired balance and compromised turning abilities are often manifested through irregularities in gait and an elevated risk of falls in individual's post-stroke. These difficulties may potentially result in injuries, restrictions in daily activities, and limitations in social engagement for people post stroke.

Complex walking and dual tasking. The achievement of safe and efficient walking relies on a delicate balance between automaticity, involving movements that require minimal attention, and executive control processes, which involve movements requiring attention. The automatic control of walking is essential for ensuring safe ambulation, allowing executive control to be directed towards other crucial aspects of the environment (e.g., navigating in crowded areas) or concurrent tasks (e.g., walking and talking on the phone). Assessment of walking automaticity commonly involves dual-tasking, where two tasks with distinct goals are performed simultaneously, such as walking while engaging in a cognitive task.

Increasing evidence indicates a strong correlation between mobility, and cognitive processes, with people post stroke documented to show the highest level of cognitive-motor interference (i.e., the relative cost of dual-tasking) when performing concurrent working memory and balance tasks. Therefore, developing and establishing robust methods to concurrently assess cortical activity and complex walking hold significant potential to provide insight into cognitive processes driving mobility in people post stroke.

Measurement of cortical activity during complex walking. While functional magnetic resonance imaging (fMRI) is considered the gold standard for functional neuroimaging, its applicability is constrained when studying gait and balance is limited. Functional near-infrared spectroscopy (fNIRS) is a novel and non-invasive imaging method that utilizes the optical properties of neuronal activity to measure changes in the concentration of oxygenated and deoxygenated hemoglobin in cortical regions. This new technology combined with the measurement of behavior (i.e., gait parameters) has the potential to measure real-time cortical activity during ecologically valid states at low costs. This is of importance for health science who often aim to study individuals' capacities to be active and participate in everyday life activities.

This study builds on previous work done by our research team, who developed and tested the feasibility of using fNIRS to measure cortical activity during different complex walking conditions in healthy adults. Promising results were found in the pilot study, and the research team further developed the protocol to include people with Parkinson's and multiple sclerosis. To date few studies have used fNIRS to investigate complex walking in people post stroke and these studies have several limitations which include homogenous and small cohorts.

The investigators are in a strong position to carry out this truly innovative research. The findings of this project will enrich the knowledge of cognitive processes driving mobility and dual tasking in people post stroke, which in turn, could facilitate the development of effective strategies and novel interventions.

PURPOSE AND GOALS The overarching purpose of this project is to clinically assess motor cognitive performance during complex walking and dual-tasking conditions by integrating a non-invasive measure of brain activity i.e. fNIRS and objective assessments of motor behavior in people post stroke. The goals of this project are to 1) validate complex walking protocols developed previously for people with neurological diseases for evaluating motor-cognitive performance and assessing brain activity using fNIRS in individual's post-stroke. 2) investigate differences in cortical activity with walking performance during complex walking tasks and compare it to healthy adults, people with Parkinson's disease and multiple sclerosis; 3) establish correlations between fNIRS-derived cortical activity and walking performance metrics (i.e., gait speed and stride length) to gain insight into the relationship between brain activity, cognitive performance, disease severity and functional outcomes in people post stroke.

MATERIALS AND METHODS Study Participants: A sample of 50 participants post stroke will be recruited through patient organizations, advertisements and established collaborating clinical sites in Stockholm (e.g., Karolinska University Hospital and Stora Sköndal).

Inclusion criteria: Individuals with a stroke ≥ 6 months confirmed by a clinical diagnosis according to established criteria before study enrollment and being able to ambulate continuously indoors with/without a walking aid for ≥5 minutes. Exclusion criteria: Individuals post stroke with cognitive impairment, severe neglect, and global aphasia affecting the ability to provide written informed consent, severe perceptual problems (e.g., spatial neglect) or severe freezing of gait.

Data collection: Prior to data collection, individuals meeting the inclusion criteria will receive written and oral information about the study. All included study participants will attend 2 sessions at the uMOVE core facility, Karolinska University Hospital, Stockholm. The assessment detailed below consists of interviews, clinical tests, gait measures, and cortical activity measurements using fNIRS and will be conducted a week apart.

Session 1 comprises:

  • Structured interviews of personal factors (e.g., age, sex, height, weight, educational level and medical history) and environmental factors (e.g., living situation, employment status, use of assistive devices).
  • Cognitive performance assessed using the Montreal Cognitive Assessment (MoCA).
  • Assessment of cortical brain activity during 3 walking protocols using fNIRS. Cortical brain activity will be measured during three walking protocols with different complex walking conditions using a block design. Each block consists of 20 seconds of stimulus followed by 15 seconds of rest period to allow for baseline measures. Protocol 1 consists of walking straight, standing still while performing an auditory Stroop task, and straight walking while performing the auditory Stroop task. Protocol 2 consists of walking straight and navigated walking. Protocol 3 consists of navigated walking and navigated walking while performing an auditory Stroop task. In the navigation condition, participants will be directed to navigate through a maze featuring a randomized arrangement of turns ranging from 90° to 225° to the left and right. The maze incorporates yellow, red, and blue cones. Participants will be specifically instructed to walk around the cones, alternating between yellow and red cones, while ignoring the blue cones. The auditory Stroop task consists of the two Swedish words for 'high' and 'low', verbally presented in a congruent and incongruent high and low pitch level through headphones.

Cortical brain activity - Changes in oxygenated (HbO) and deoxygenated (HHb) hemoglobin in the prefrontal cortex will be measured using the NIRSPORT 2 (NIRx Medizintechnik, Berlin, Germany) continuous wave fNIRS device. During each protocol, the participants will be fitted with an fNIRS cap with 16 sources and 16 detectors, and a controller box attached to a backpack harness. The source optodes transmit infrared light at 760 and 850 nm and the detector optodes record changes in HbO and HHb at 10 Hz. Optode placement will be arranged according to the international 10-20 system over the prefrontal area.The fNIRS data will be streamed wirelessly to a local computer using the Aurora software.

Measurement of gait and behavioral parameters - Simultaneously gait parameters (e.g., walking speed and cadence) will be measured using 3 inertial measurement units (OPAL APDM inc.) positioned at on top of each foot and around the lumbar. The sensors will continuously stream data to a local computer using the Mobility LabTM software. To measure mistakes during navigational walking the investigators will mount a GoPro camera on the chest of each participant pointing to the feet. Additionally, the auditory Stroop verbal responses will be recorded through headphones using the Audacity software (version 2.4.2).

Session 2 comprises questionnaires and clinical assessments:

  • Stroke Severity measured using the National Institutes of Health Stroke Scale (NIHSS).
  • Stroke-specific health status measured using the Stroke Impact Scale (SIS).
  • Physical impairment measured using the Chedoke McMaster Stroke Assessment.
  • Fatigue measured using the Fatigue Severity Scale (FSS).
  • Walking ability measured using the Walk-12G.
  • Balance performance measured using the Mini-BESTest.
  • Anxiety and Depression measured using the Hospital Anxiety and Depression Scale (HADS).
  • Cognitive performance will be assessed using the Montreal Cognitive Assessment (MoCA), Trail Making Tests, Ray Auditory Verbal Learning Test (RAVLT) and Color and Word Test from the Delis-Kaplan Function System ( D-KEFS).

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Arvioitu)

50

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

  • Nimi: Compliance Office Karolinska Insitutet
  • Puhelinnumero: +46852480000
  • Sähköposti: compliance@ki.se

Tutki yhteystietojen varmuuskopiointi

  • Nimi: Erika Franzén, PhD professor
  • Puhelinnumero: +46852488878
  • Sähköposti: erika.franzen@ki.se

Opiskelupaikat

    • Stockholm County
      • Solna, Stockholm County, Ruotsi, 17177
        • Rekrytointi
        • uMOVE core facility, Karolinska Institutet and Karolinska University hospital
        • Ottaa yhteyttä:
        • Päätutkija:
          • Erika Franzén, Professor
        • Päätutkija:
          • Lucian Bezuidenhout, PhD

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Ei

Näytteenottomenetelmä

Ei-todennäköisyysnäyte

Tutkimusväestö

We are studying complex walking in four different populations, people with stroke, healthy adults, people with Parkinson's disease and people with Multiple Sclerosis. We have during 2022-2025 completed data collection (ClinicalTrials.gov ID: NCT06906276, NCT05218213 and NCT05787704) of healthy adults, people with Parkinson's disease and people with Multiple Sclerosis. Hence, this registration concerns the stroke cohort

Kuvaus

Inclusion Criteria:

  • 18 years or older
  • with a stroke ≥6 months confirmed by a clinical diagnosis
  • with the ability to walk with or without a walking aid for ≥ 5 min

Exclusion Criteria:

  • Individuals post stroke with cognitive impairment
  • severe neglect
  • global aphasia affecting the ability to provide written informed consent
  • severe perceptual problems or severe freezing of gait

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

Kohortit ja interventiot

Ryhmä/Kohortti
Interventio / Hoito
Individuals with a stroke ≥ 6 months

This study includes assessment of brain activity with functional Near Infrared Spectrscopy (fNIRS) and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.

Dual-task walking with the auditory stroop task. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right Navigational and dual-task walking (condition 1 and 2 together)

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Functional near infrared spectrometry (fNIRS)
Aikaikkuna: Baseline
The measurement of changes in concentration of oxygenated hemoglobin (HbO) and deoxygenated hemoglobin (HHb) in the prefrontal cortex will be assessed using a NIRSPORT 2 (NIRx Medizintechnik, Berlin, Germany) device.
Baseline
Stride time during all conditions
Aikaikkuna: Baseline
Stride time will be analyzed with the APDM mobility system.
Baseline
Velocity during all conditions
Aikaikkuna: Baseline
Velocity will be analyzed with the APDM mobility system.
Baseline
Dual-task performance-reaction time
Aikaikkuna: Baseline
Cognitive performance of the dual task will be assessed as errors in the response to the Auditory stroop task.
Baseline

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Kognitiivinen toiminta - sanallinen sujuvuus
Aikaikkuna: Lähtökohta
Sanallinen toiminto, aloittaminen ja tehtävä-asetettu kytkentä D-KEFS: n (Delis-Kaplanin toimeenpanotoimintojärjestelmä) sanallisen sujuvuustestin kanssa.
Lähtökohta
Kognitiivinen toiminta - huomio ja psykomotorinen prosessointinopeus
Aikaikkuna: Lähtökohta
Huomio- ja psykomotorisen prosessointinopeus arvioidaan D-KEFS: n (Delis-Kaplanin toimeenpanotoimintojärjestelmän) polunvalmistustestillä (TMT).
Lähtökohta
Kognitiivinen funktio - episodinen muisti
Aikaikkuna: Lähtökohta
Episodinen muisti arvioidaan Ray Audit Varallinen oppimistesti (RavLT).
Lähtökohta
Cognitive performance
Aikaikkuna: Baseline
Global cognitive performance will be assessed with the Montreal Cognitive Assessment (MoCA). Scores range from 0-30, with higher score indicating better performance.
Baseline
Stroke severity
Aikaikkuna: Baseline
Assessed using the National Institutes of Health Stroke Scale (NIHSS). Scores range from 0-42, with higher scores indicating greater stroke severity.
Baseline
Stroke specific health status
Aikaikkuna: Baseline
Assessed using the Stroke Impact Scale (SIS). Scores range from 0-100, with higher scores indicating better functioning
Baseline
Physical Impairment
Aikaikkuna: Baseline
Assessed using the Chedoke McMaster Stroke Assessment. Scores range from 1-7 for each impairment dimension, with higher scores indicating better motor recovery.
Baseline
Walking ability
Aikaikkuna: Baseline
Assessed using the Walk-12G. Scores range from 0-42, with higher scores indicating greater walking difficulties
Baseline
Balance performance
Aikaikkuna: Baseline
Assessed with the Mini-BESTest (Balance Evaluation Systems test). Scores range from 0-28, with higher scores indicating better balance performance.
Baseline
Anxiety and Deprssion
Aikaikkuna: Baseline
Assessed with Hospital Anxiety and Depression Scale (HADS). Scores range from 0-24 for the anxiety and depression subscales, respectively, with lower scores indicating fewer symptoms of anxiety and depression
Baseline
Self-reported level of physical activity
Aikaikkuna: Baseline
Assessed with the Frändin-Grimby Scale. Scores range from 1-6, with higher scores indicating higher levels of physical activity.
Baseline
Physical activity levels
Aikaikkuna: Baseline
Assessed with acceleromters (Actigraph GT3X+)
Baseline
Dual-task performance -errors
Aikaikkuna: Baseline
Cognitive performance of the dual task will be assessed as the reaction time to respond during Auditory stroop
Baseline
Navigation errors
Aikaikkuna: Baseline
Assessed using a GoPro camera
Baseline

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Lauantai 1. elokuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Torstai 1. heinäkuuta 2027

Opintojen valmistuminen (Arvioitu)

Torstai 1. heinäkuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 13. toukokuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 1. kesäkuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 3. kesäkuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Keskiviikko 3. kesäkuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 1. kesäkuuta 2026

Viimeksi vahvistettu

Maanantai 1. kesäkuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

The datasets generated during and/or analysed during the current study are not publicly available due to Swedish and EU personal data legislation but are available from the principal investigator on reasonable request. Any sharing of data will be regulated via a data transfer and user agreement with the recipient.

IPD-jaon aikakehys

We plan to share this when applicable on OSF or similar

IPD-jaon käyttöoikeuskriteerit

The datasets generated during and/or analysed during the current study are not publicly available due to Swedish and EU personal data legislation but are available from the principal investigator on reasonable request. Any sharing of data will be regulated via a data transfer and user agreement with the recipient.

IPD-jakamista tukeva tietotyyppi

  • MAHLA
  • ANALYTIC_CODE

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa